Advancing depression treatment: the role of sigma receptor ligands
Peng Zhang1,2, Zeqiong Ning3, Haixia Chen1
1Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, The Fourth Military Medical University, Key Laboratory of Anesthesiology (The Fourth Military Medical University), Ministry of Education, Shaanxi Provincial Clinical Research Center for Anesthesiology Medicine, Xi'an, China.
Abstract:
Depression, one of the most prevalent neuropsychiatric disorders, continues to pose escalating global health challenges. Despite the discovery of numerous antidepressants, their clinical applications are limited, and there is still an urgent need to identify more effective antidepressant drugs and their molecular targets. In recent years, sigma receptors have garnered considerable interest among depression researchers because of their diverse biological functions and significant roles in the central nervous system. This review provides a comprehensive summary of the potential roles of sigma receptors and their ligands in the pathogenesis of depression and the course of antidepressant treatment, with the aim of offering insights into further research and potential therapeutic development.
Related Concept Videos
G-protein Coupled Receptors
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...


